• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Orchard Therapeutics plc (Amendment)

    4/10/23 11:39:12 AM ET
    $ORTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ORTX alert in real time by email
    SC 13G/A 1 form945.htm

    OMB APPROVAL

    OMB Number: 3235-0145

    Estimated average burden hours per response ….11

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2*)

    ORCHARD THERAPEUTICS, PLC

    (Name of Issuer)

    COMMON STOCK

    (Title of Class of Securities)

    68570P101

    (CUSIP Number)

    March 31, 2023

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    X Rule 13d-1(b)
      Rule 13d-1(c)
      Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     
     

     

    CUSIP No.: 68570P101

    1. Names of Reporting Persons
      I.R.S. Identification Nos. of above persons (entities only)
      Federated Hermes, Inc.
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a)
      (b)
    3. SEC Use Only
    4. Citizenship or place of Organization: Pennsylvania

     

    Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power:     840,169
    6. Shared Voting Power
    7. Sole Dispositive Power:     840,169
    8. Shared Dispositive Power

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person:     840,169
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    11. Percent of Class Represented by Amount in Row (9):  4.57%
    12. Type of Reporting Person (See Instructions): HC

     

    1. Names of Reporting Persons
      I.R.S. Identification Nos. of above persons (entities only)
      Voting Shares Irrevocable Trust
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a)
      (b)
    3. SEC Use Only
    4. Citizenship or place of Organization: Pennsylvania

     

    Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power:     840,169
    6. Shared Voting Power
    7. Sole Dispositive Power:     840,169
    8. Shared Dispositive Power

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person:     840,169
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    11. Percent of Class Represented by Amount in Row (9):  4.57%
    12. Type of Reporting Person (See Instructions): OO

     

    1. Names of Reporting Persons
      I.R.S. Identification Nos. of above persons (entities only)
      Thomas R. Donahue
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a)
      (b)
    3. SEC Use Only
    4. Citizenship or place of Organization: United States

     

    Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power:
    6. Shared Voting Power:     840,169
    7. Sole Dispositive Power
    8. Shared Dispositive Power:     840,169

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person:     840,169
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    11. Percent of Class Represented by Amount in Row (9):  4.57%
    12. Type of Reporting Person (See Instructions): IN

     

    1. Names of Reporting Persons
      I.R.S. Identification Nos. of above persons (entities only)
      Ann C. Donahue
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a)
      (b)
    3. SEC Use Only
    4. Citizenship or place of Organization: United States

     

    Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power:
    6. Shared Voting Power:     840,169
    7. Sole Dispositive Power
    8. Shared Dispositive Power:     840,169

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person:     840,169
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    11. Percent of Class Represented by Amount in Row (9):  4.57%
    12. Type of Reporting Person (See Instructions):IN

     

    1. Names of Reporting Persons
      I.R.S. Identification Nos. of above persons (entities only)
      J. Christopher Donahue
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a)
      (b)
    3. SEC Use Only
    4. Citizenship or place of Organization: United States

     

    Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power:
    6. Shared Voting Power:     840,169
    7. Sole Dispositive Power
    8. Shared Dispositive Power:     840,169

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person:     840,169
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    11. Percent of Class Represented by Amount in Row (9):  4.57%
    12. Type of Reporting Person (See Instructions): IN

     

    Item 1.

    (a) Name of Issuer
      ORCHARD THERAPEUTICS, PLC
    (b) Address of Issuer’s Principal Executive Offices
      245 Hammersmith Road, 3rd Floor
      London, United Kingdom W6 8PW

    Item 2.

    (a) Name of Person Filing: Federated Hermes, Inc.
    (b) Address Of Principal Business Office or, if none, Residence
      1001 Liberty Avenue, Pittsburgh, PA  15222-3779
    (c) Citizenship: Pennsylvania
    (d) Title of Class of Securities
      Common Stock
    (e) CUSIP Number: 68570P101
    Item 3.If this statement is filed pursuant to §§240.113d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)   An investment adviser in accordance with §204.13d-1(b)(1)(ii)(E);
    (f)   An employee benefit plan or endowment fund in accordance with §240.13d-19b)(1)(ii)(F);
    (g) X A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
    (h)   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)   Group, in accordance with §240.13d-1(b)(1)(ii)(J).
    Item 4.Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    A. Federated Hermes, Inc.
    (a) Amount beneficially owned:     840,169
    (b) Percent of class:  4.57%
    (c) Number of shares to which the person has:
      (i) Sole power to vote or to direct the vote:     840,169
      (ii) Shared power to vote or to direct the vote:  0
      (iii) Sole power to dispose or to direct the disposition of:     840,169  
      (iv) Shared power to dispose or to direct the disposition of:  0

     

    B. Voting Shares Irrevocable Trust
    (a) Amount beneficially owned:     840,169
    (b) Percent of class:  4.57%
    (c) Number of shares to which the person has:
      (i) Sole power to vote or to direct the vote:     840,169
      (ii) Shared power to vote or to direct the vote:  0
      (iii) Sole power to dispose or to direct the disposition of:     840,169  
      (iv) Shared power to dispose or to direct the disposition of:  0

     

     

    C. Thomas R. Donahue
    (a) Amount beneficially owned:     840,169
    (b) Percent of class:  4.57%
    (c) Number of shares to which the person has:
      (i) Sole power to vote or to direct the vote:  0
      (ii) Shared power to vote or to direct the vote:     840,169
      (iii) Sole power to dispose or to direct the disposition of:  0
      (iv) Shared power to dispose or to direct the disposition of:     840,169  

     

    D. Ann C. Donahue
    (a) Amount beneficially owned:     840,169
    (b) Percent of class:  4.57%
    (c) Number of shares to which the person has:
      (i) Sole power to vote or to direct the vote:  0
      (ii) Shared power to vote or to direct the vote:     840,169
      (iii) Sole power to dispose or to direct the disposition of:  0
      (iv) Shared power to dispose or to direct the disposition of:     840,169

     

     

    E. J. Christopher Donahue
    (a) Amount beneficially owned:     840,169
    (b) Percent of class:  4.57%
    (c) Number of shares to which the person has:
      (i) Sole power to vote or to direct the vote:  0
      (ii) Shared power to vote or to direct the vote:     840,169
      (iii) Sole power to dispose or to direct the disposition of:  0
      (iv) Shared power to dispose or to direct the disposition of:     840,169

     

    Instruction: Dissolution of a group requires a response to this item.

    Item 5.Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: X

    Instruction: Dissolution of a group requires a response to this item.

    Item 6.Ownership of More than Five Percent on Behalf of Another Person. NOT APPLICABLE
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See Exhibit “1” Attached
    Item 8.Identification and Classification of Members of the Group: NOT APPLICABLE
    Item 9.Notice of Dissolution of Group: NOT APPLICABLE
    Item 10.Certification
    (a) The following certification shall be included if the statement is filed pursuant to §240.13d-1(b);
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having the purpose or effect.
    (b) The following certification shall be included if the statement is filed pursuant to §204.13d-1(c):
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: April 10, 2023
    By: /s/J. Christopher Donahue
    Name/Title: J. Christopher Donahue, as President of Federated Hermes, Inc.
       
    Date: April 10, 2023
    By: /s/Thomas R. Donahue
    Name/Title Thomas R. Donahue individually and as Trustee of Voting Shares Irrevocable Trust
       
    Date: April 10, 2023
    By: /s/Ann C. Donahue
    Name/Title: Ann C. Donahue individually and as Trustee of Voting Shares Irrevocable Trust
       
    Date: April 10, 2023
    By: /s/J. Christopher Donahue
    Name/Title J. Christopher Donahue individually and as Trustee of Voting Shares Irrevocable Trust
       

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties for whom copies are to be sent.

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See U.S.C. 1001)

     
     

     

    EXHIBIT “1”

    ITEM 3 CLASSIFICATION OF REPORTING PERSONS

    Identity and Classification of Each Reporting Person

     

    IDENTITY CLASSIFICATION UNDER ITEM 3
    Federated Hermes Equity Funds (d) Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)
    Federated Hermes Insurance Series (d) Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)
    Federated Equity Management Company of Pennsylvania (e) Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940
    Federated Global Investment Management Corp. (e) Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940
    Federated Hermes, Inc. (g) parent Holding Company or control person, in accordance with Section 240.13d-1(b)(ii)(G)
    FII Holdings, Inc. (g) parent Holding Company or control person, in accordance with Section 240.13d-1(b)(ii)(G)
    Voting Shares Irrevocable Trust (g) parent Holding Company or control person, in accordance with Section 240.13d-1(b)(ii)(G)
    Thomas R. Donahue (g) parent Holding Company or control person, in accordance with Section 240.13d-1(b)(ii)(G)
    Ann C. Donahue (g) parent Holding Company or control person, in accordance with Section 240.13d-1(b)(ii)(G)
    J. Christopher Donahue (g) parent Holding Company or control person, in accordance with Section 240.13d-1(b)(ii)(G)

    Federated Hermes, Inc. (the “Parent”) is filing this schedule 13G because it is the parent holding company of Federated Equity Management Company of Pennsylvania and Federated Global Investment Management Corp. (the “Investment Advisers”), which act as investment advisers to registered investment companies and separate accounts that own shares of common stock in ORCHARD THERAPEUTICS, PLC (the “Reported Securities”). The Investment Advisers are wholly owned subsidiaries of FII Holdings, Inc., which is wholly owned subsidiary of Federated Hermes, Inc., the Parent. All of the Parent’s outstanding voting stock is held in the Voting Shares Irrevocable Trust (the “Trust”) for which Thomas R. Donahue, Ann C. Donahue and J. Christopher Donahue act as trustees (collectively, the “Trustees”). The Trustees have joined in filing this Schedule 13G because of the collective voting control that they exercise over the Parent. In accordance with Rule 13d-4 under the Securities Act of 1934, as amended, the Parent, the Trust, and each of the Trustees declare that this statement should not be construed as an admission that they are the beneficial owners of the Reported Securities, and the Parent, the Trust, and each of the Trustees expressly disclaim beneficial ownership of the Reported Securities.

     
     

    EXHIBIT “2”

    AGREEMENT FOR JOINT FILING OF

    SCHEDULE 13G

    The following parties hereby agree to file jointly the statement on Schedule 13G to which this Agreement is attached and any amendments thereto which may be deemed necessary pursuant to Regulation 13D-G under the Securities Exchange Act of 1934:

    1.       Federated Hermes, Inc. as parent holding company of the investment advisers to registered investment companies that beneficially own the securities.

    Voting Shares Irrevocable Trust, as holder of all the voting shares of Federated Hermes, Inc.

    Thomas R. Donahue, individually and as Trustee

    Ann C. Donahue, individually and as Trustee

    J. Christopher Donahue, individually and as Trustee

    It is understood and agreed that each of the parties hereto is responsible for the timely filing of such statement any amendments thereto, and for the completeness and accuracy of the information concerning such party contained therein, but such party is not responsible for the completeness or accuracy of information concerning the other parties unless such party knows or has reason to believe that such information is incomplete or inaccurate.

    It is understood and agreed that the joint filing of Schedule 13G shall not be construed as an admission that the reporting persons named herein constitute a group for purposes of Regulation 13D-G of the Securities Exchange Act of 1934, nor is a joint venture for purposes of the Investment Company Act of 1940.

    Date: April 10, 2023

    By: /s/J. Christopher Donahue
    Name/Title: J. Christopher Donahue, as President of Federated Hermes, Inc.
       
    By: /s/Thomas R. Donahue
    Name/Title Thomas R. Donahue, individually and as Trustee of Voting Shares Irrevocable Trust.
       
    By: /s/Ann C. Donahue
    Name/Title Ann C. Donahue, individually and as Trustee of Voting Shares Irrevocable Trust
       
    By: /s/J. Christopher Donahue
    Name/Title J. Christopher Donahue, individually and as Trustee of Voting Shares Irrevocable Trust

    1.       The number of shares indicated represent shares beneficially owned by registered investment companies and separate accounts advised by subsidiaries of Federated Hermes, Inc. that have been delegated the power to direct investment and power to vote the securities by the registered investment companies’ board of trustees or directors and by the separate accounts’ principals. All of the voting securities of Federated Hermes, Inc. are held in the Voting Shares Irrevocable Trust (“Trust”), the trustees of which are Thomas R. Donahue, Ann C. Donahue and J. Christopher Donahue (“Trustees”). In accordance with Rule 13d-4 under the 1934 Act, the Trust, Trustees, and parent holding company declare that the filing of this statement should not be construed as an admission that any of the investment advisers, parent holding company, Trust, and Trustees are beneficial owners (for the purposes of Sections 13(d) and/or 13(g) of the Act) of any securities covered by this statement, and such advisers, parent holding company, Trust, and Trustees expressly disclaim that they are the beneficial owners of such securities.

     
     

     

    EXHIBIT “3”

     

     

    EXHIBIT “3”

     

     

     

    Text, letter

Description automatically generated

    Get the next $ORTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ORTX

    DatePrice TargetRatingAnalyst
    12/29/2021$12.00 → $9.00Overweight
    Cantor Fitzgerald
    11/16/2021Neutral → Underweight
    JP Morgan
    11/5/2021$15.00 → $13.00Outperform
    Oppenheimer
    8/18/2021Overweight → Neutral
    JP Morgan
    More analyst ratings

    $ORTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald resumed coverage on Orchard Therapeutics with a new price target

      Cantor Fitzgerald resumed coverage of Orchard Therapeutics with a rating of Overweight and set a new price target of $9.00 from $12.00 previously

      12/29/21 7:21:48 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Orchard Therapeutics downgraded by JP Morgan

      JP Morgan downgraded Orchard Therapeutics from Neutral to Underweight

      11/16/21 5:23:39 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Oppenheimer reiterated coverage on Orchard Therapeutics with a new price target

      Oppenheimer reiterated coverage of Orchard Therapeutics with a rating of Outperform and set a new price target of $13.00 from $15.00 previously

      11/5/21 9:48:29 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ORTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Orchard Therapeutics plc

      SC 13G - Orchard Therapeutics plc (0001748907) (Subject)

      2/14/24 9:05:44 PM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Orchard Therapeutics plc (Amendment)

      SC 13G/A - Orchard Therapeutics plc (0001748907) (Subject)

      2/14/24 6:35:58 PM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Orchard Therapeutics plc (Amendment)

      SC 13G/A - Orchard Therapeutics plc (0001748907) (Subject)

      2/12/24 12:03:27 PM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ORTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024

      TOKYO, LONDON and BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced four oral and four poster presentations from across its hematopoietic stem cell (HSC) gene therapy platform will be featured at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) taking place May 7-11, 2024, in Baltimore. Featured data include several accepted abstracts and an Oral Presidential Symposium supporting the safety and efficacy of atidarsagene autotemcel (formerly OTL-200 which was recently approved as Lenmeldy™ in the

      5/7/24 7:00:17 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List

      TOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced that Bobby Gaspar, M.D., Ph.D., co-founder and chief executive officer, has been named to the inaugural 2024 TIME100 Health, an annual list recognizing the impact, innovation, and achievement of the world's most influential individuals in health this year. The full list and related tributes will appear in the May 13, 2024 issue of TIME and is available online at https://time.com/collection/time100-health/. "I am incredibly humbled, privileged, and immensely proud to b

      5/3/24 7:00:38 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy

      Five specialized treatment centers being qualified across the U.S. to minimize travel burden on eligible patients and their families Orchard Assist patient services program to provide individualized support throughout the treatment process Lenmeldy wholesale acquisition cost of $4.25 million for one-time treatment reflects its clinical, economic and societal value Innovative outcomes- and value-based agreements are being offered to both private and government insurers to ensure broad, expedient and sustainable reimbursed access TOKYO, LONDON and BOSTON, March 20, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the de

      3/20/24 7:00:07 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ORTX
    Financials

    Live finance-specific insights

    See more
    • Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases

      TOKYO and LONDON and BOSTON, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a Japan-based global specialty pharmaceutical company (J-GSP) discovering and developing novel medicines utilizing the latest biotechnology, and Orchard Therapeutics plc ((Orchard Therapeutics, NASDAQ:ORTX), a global gene therapy leader, today announced Kyowa Kirin has successfully completed the acquisition of Orchard Therapeutics. The acquisition of all outstanding shares of Orchard Therapeutics by way of a Scheme of Arrangement procedure under the UK Companies Act 2006 was completed on January 24, 2024, and Orchard Therapeutics has become a wholly-owned subsidiary of Kyowa Kirin.

      1/24/24 5:00:00 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kyowa Kirin to Acquire Orchard Therapeutics

      -Orchard Therapeutics is a global gene therapy leader with experience successfully developing and commercializing medicines for rare diseases--Acquisition enriches Kyowa Kirin's portfolio, enables the development of numerous promising candidates with a clinically differentiated platform, and helps resource the ongoing and future launches of Libmeldy® (atidarsagene autotemcel)--Acquisition price of $16.00 per ADS in cash plus an additional contingent value right of $1.00 per ADS, representing a total maximum equity value of approximately $477.6 million--Kyowa Kirin to host investor conference call on Oct 5 at 18:30 p.m. JST- TOKYO and LONDON and BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Ky

      10/5/23 3:35:06 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Orchard Therapeutics Completes Submission of Biologics License Application for OTL-200 in MLD to U.S. FDA

      Reported $6.6M in Q2'23 Libmeldy net sales, representing the highest quarter to date $34.0M of additional capital from second closing of strategic financing extends runway to mid-2025 Four MLD patients identified from ~150,000 newborns screened in prospective studies suggests significantly higher incidence than previously estimated in the medical literature Six presentations at ASGCT demonstrate the ability of HSC gene therapy to address neurometabolic and CNS disorders, as well as larger indications Company to host conference call and live webcast today at 8:00 a.m. EDT BOSTON and LONDON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene th

      8/3/23 7:00:09 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ORTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments

      Reported $5.6 million in quarterly Libmeldy net revenue and $12.7 million year-to-date Planned acquisition by Kyowa Kirin valued at up to $477.6 million with an anticipated closing in the first quarter of 2024 Biologics License Application for OTL-200 in MLD accepted by U.S. FDA under Priority Review; PDUFA date set for March 18, 2024 Ten prospective newborn screening studies are active globally with approximately 200,000 babies screened Eight presentations at ESGCT highlighted the differentiated profile and potential broad applicability of the company's HSC gene therapy platform BOSTON and LONDON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene the

      11/13/23 7:00:00 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • OMass Therapeutics Announces Appointment of New Board Chair and Series B Extension

      PRESS RELEASE OMass Therapeutics Announces Appointment of New Board Chairand Series B Extension Jim Geraghty joins as Independent Director and Chair, bringing US and international experience from Genzyme and as NED and chair of multiple listed biotechsBritish Patient Capital invests £10 million in a Series B extension bringing total raised in this round to £85.5 million Oxford, United Kingdom – 15 May 2023 – OMass Therapeutics (‘OMass', or ‘the Company'), a biotechnology company that identifies medicines against highly validated target ecosystems, today announces the appointment of Jim Geraghty as chairman of its board of directors and an additional investment of £10 million from new inve

      5/15/23 2:00:00 AM ET
      $FULC
      $ORTX
      $PIRS
      $VYGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Orchard Therapeutics Bolsters R&D and Technical Operations Leadership with New Executive Appointments

      Gene therapy experts Fulvio Mavilio, Ph.D., and Nicoletta Loggia, Ph.D., join as chief scientific officer and chief technical officer, respectively Neuroscience and rare disease leader Leslie Meltzer, Ph.D., promoted to chief medical officer Appointments reinforce company's strategic focus on innovation in the areas of discovery, clinical development and manufacturing BOSTON and LONDON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced the appointment of two gene therapy and industry experts, Fulvio Mavilio, Ph.D., and Nicoletta Loggia, Ph.D., to serve as chief scientific officer and chief technical officer, respectively

      9/9/21 7:00:00 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ORTX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Orchard Therapeutics plc

      15-12G - Orchard Therapeutics plc (0001748907) (Filer)

      2/5/24 2:39:49 PM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Orchard Therapeutics plc

      EFFECT - Orchard Therapeutics plc (0001748907) (Filer)

      1/31/24 12:15:05 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Orchard Therapeutics plc

      EFFECT - Orchard Therapeutics plc (0001748907) (Filer)

      1/31/24 12:15:12 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ORTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Secor Alicia

      4 - Orchard Therapeutics plc (0001748907) (Issuer)

      1/24/24 5:34:09 PM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Geraghty James A returned 44,391 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Orchard Therapeutics plc (0001748907) (Issuer)

      1/24/24 5:29:38 PM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Thomas Frank E returned 92,081 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Orchard Therapeutics plc (0001748907) (Issuer)

      1/24/24 5:27:31 PM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care